The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC).
 
Brian I. Rini
Consulting or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Thomas Powles
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
 
Mei Chen
Employment - Merck
 
Markus Puhlmann
Employment - Merck
Stock and Other Ownership Interests - Merck
Honoraria - Merck
Travel, Accommodations, Expenses - Merck
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Alkermes; Amgen; Bristol-Myers Squibb; C-Cam; Genentech; Genoptix; GlaxoSmithKline; Infinity Pharmaceuticals; Lilly; Merck; Nektar; Novartis; Pfizer; X4 Pharma